Prothena Corp Public (PRTA) Change in Accured Expenses (2012 - 2026)
Prothena Corp Public (PRTA) recorded quarterly Change in Accured Expenses of -$2.2 million in Q1 2026, up 64.44% quarter-over-quarter from -$6.2 million in Q4 2025, and down 344.18% on a YoY basis from $910000.0 in Q1 2025.
Prothena Corp Public (PRTA) Change in Accured Expenses (2012 - 2026) Analysis & Trends
Prothena Corp Public's Change in Accured Expenses history runs 15 years deep, the most recent figure standing at -$2.2 million for Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 344.18% year-over-year to -$2.2 million; the TTM figure through Mar 2026 stood at -$18.9 million (down 544.66% YoY), while the FY2025 annual figure was -$15.8 million, up 13.78% from the prior year.
- Change in Accured Expenses was -$2.2 million for Q1 2026 at Prothena Corp Public, up from -$6.2 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $8.6 million in Q2 2023 to a low of -$14.5 million in Q1 2024.
- Historically, Change in Accured Expenses has averaged -$92705.9 across 5 years, with a median of $910000.0 in 2025.
- The sharpest annual moves came in 2023 and 2024: Change in Accured Expenses soared 11076.92% in 2023, then plunged 936.52% in 2024.
- A 5-year view of Change in Accured Expenses shows it stood at $39000.0 in 2022, then jumped by 11076.92% to $4.4 million in 2023, then plunged by 54.32% to $2.0 million in 2024, then slumped by 413.86% to -$6.2 million in 2025, then surged by 64.44% to -$2.2 million in 2026.
- The last three Change in Accured Expenses figures came in at -$2.2 million (Q1 2026), -$6.2 million (Q4 2025), and -$1.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 931,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 70.50 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Prothena Corp Public | 479.08 Mn | 149.61 Mn | - | -2.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.22 Mn |
| Mar 31, 2026 | -2.22 Mn |
| Dec 31, 2025 | -6.25 Mn |
| Dec 31, 2025 | -6.25 Mn |
| Sep 30, 2025 | -1.63 Mn |
| Sep 30, 2025 | -1.63 Mn |
| Jun 30, 2025 | -8.81 Mn |
| Jun 30, 2025 | -8.81 Mn |
| Mar 31, 2025 | 910,000.00 |
| Mar 31, 2025 | 910,000.00 |
| Dec 31, 2024 | 1.99 Mn |
| Dec 31, 2024 | 1.99 Mn |
| Sep 30, 2024 | -1.19 Mn |
| Sep 30, 2024 | -1.19 Mn |
| Jun 30, 2024 | -4.65 Mn |
| Jun 30, 2024 | -4.65 Mn |
| Mar 31, 2024 | -14.46 Mn |
| Mar 31, 2024 | -14.46 Mn |
| Dec 31, 2023 | 4.36 Mn |
| Dec 31, 2023 | 4.36 Mn |